MDACC Study No:2012-0661 ( NCT No: NCT01712490)
Title:A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in
Patients With Advanced Classical Hodgkin Lymphoma
Principal Investigator:Yasuhiro Oki
Treatment Agent:Bleomycin; Dacarbazine; Doxorubicin; SGN-35; Vinblastine
Study Status:Open
Study Description:In this study, you will receive one of two regimens, either a regimen that
includes an investigational drug called brentuximab vedotin (also known as
ADCETRISTM) (this regimen/group is referred to as Arm A) or a commonly
prescribed regimen (this regimen/group is referred to as Arm B) – these
regimens will be described in more detail in section 3. ADCETRIS has been
approved in the United States by the Food and Drug Administration (FDA) as
ADCETRIS for treatment of some types of lymphoma in patients where other
therapies have failed. The use of ADCETRIS in this study is experimental,
which means that the drug has not been approved by the FDA for use in patients
that have not received any treatment for their HL (also known as frontline

The main purpose of this study is to measure how well treatment in Arm A works
compared to treatment in Arm B for Hodgkin lymphoma.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase III
Treatment Agents:Bleomycin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Millennium Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yasuhiro Oki
For Clinical Trial Enrollment:713-792-2806
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults